Moreover, the untreated OSA group had poorer final visual acuity and thinner maculas than the CPAP‐treated group after completing the anti‐VEGF injection regimens (visual acuity: 0.7 vs. 0.3 logMAR; macular thickness: 322 vs. 254 μm), despite having similar baseline measures prior to anti‐VEGF therapy.84 Here, VEGFA is linked to obstructive sleep apnea syndrome.